On April 1, 2025 Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company with two programs in clinical-stage development, reported the departure of Dr. Brendan Eckelman, co-founder and Chief Scientific Officer (CSO) and the appointments of Dr. Carlos Bais and David Matly to CSO and President, respectively (Press release, Inhibrx, APR 1, 2025, View Source [SID1234651729]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. Eckelman leaves the Company to establish a newly-formed private biotechnology company, where he will be founder and Chief Executive Officer. Inhibrx and the new company have entered into an exclusive license agreement for the rights to certain technologies no longer being pursued by Inhibrx. The agreement includes an upfront payment upon completion of the initial funding of Dr. Eckelman’s new company and other future development milestones.
"I would like to express my deep gratitude to Brendan for his extraordinary contributions to Inhibrx over the last 15 years," said Mark Lappe, CEO of Inhibrx. "Brendan has had a profound impact on Inhibrx and we expect he will lead this next endeavor to the same success."
"I am immensely proud of the achievements and groundbreaking innovations we have developed since co-founding Inhibrx in 2010. As I announce my departure, it is a bittersweet moment.," says Dr. Eckelman. "I have the utmost confidence in the team and the culture of innovation I’m leaving behind and look forward to continuing to support Inhibrx in my capacity as a shareholder."
Dr. Carlos Bais, the Company’s current Executive Vice President of Translational Sciences, will be appointed to CSO following Dr. Eckelman’s departure.
Additionally, the Company also announced the promotion of David Matly to President in addition to his existing roles as Chief Commercial and Business Development Officer. In David’s new role as President, he will continue to lead the commercial and business development functions as well as oversee clinical development and operations, R&D, technical operations and regulatory affairs. Notably, David played a key leadership role in Inhibrx, Inc.’s asset sale of INBRX-101 to Sanofi for up to $2.2B in 2024.
"We believe we are exceptionally well-positioned for continued success as Carlos steps into the role of CSO and David into the role of President," continued Mr. Lappe. "Carlos’s strong scientific background and expertise in late-stage development make him a perfect candidate to assume the CSO role. And David’s cross-functional understanding of successfully delivering best-in-class new therapies, combined with his ambition and commitment to the Company will prove to be pivotal to our future success. Each will play a crucial role as we continue to execute on our clinical programs in an effort to deliver significant impact to patients while maximizing the value to our shareholders."